Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchSipavibartSipavibart (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

 
    
  
$0 $1,000 $2,000+ -25+% 0% 25% 50% Treatment cost (US$) Efficacy vs. cost for COVID-19 treatments Donidalorsen -151% >$2,000 Glenzocimab -60% >$2,000 Olokizumab -50% >$2,000 PPIs -46% BMS mAbs -36% >$2,000 Acetaminophen -28% Lufotrelvir >$2,000 Trimodulin >$2,000 Plitidepsin >$2,000 Losartan Sargramostim >$2,000 Cannabidiol Vitamin B9 Conv. Plasma $5,000 Remdesivir $3,120 Sarilumab >$2,000 Acebilustat >$2,000 Ibuprofen Aspirin Molnupiravir mutagenic/teratogenic Favipiravir Paxlovid Famotidine Vitamin C Amubarvimab/r.. NAC Vilobelimab $6,350 Sotrovimab $2,100 Colchicine Budesonide Probiotics Zinc HCQ Azvudine Antiandro.. Nitric Oxide Sleep Metformin Bebtelovimab Vitamin A Vitamin D Sunlight H. Peroxide Exercise Fluvox. H1RAs Curcumin Casirivimab/i.. $2,100 Tixagevimab/c.. N. Sativa NaHCO₃ Melatonin Ensovibep >$2,000 Quercetin Bamlanivimab/e.. pH+ Diet PVP-I Thermotherapy Ivermectin Regdanvimab $2,100 Lifestyle / free No prescription Prescription required High-cost Lowerrisk Higherrisk c19early.org December 2024 COVID-19 involves the interplay of 50+ host/viral proteins/factors, modulated by many treatments. 0.5% of 8,000+proposed treatments show efficacy with ≥3 studies.Protocols combine treatments, none are 100% effective.c19early analyzes over 5,100 studies for 112 treatments.
Home   Post   Share   @CovidAnalysis   OutcomesOutcomes   mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Casadevall, Choudhary, Günther, Leducq. Recent:
Loubet
Planas.
Submit updates/corrections. Summary.
Sep 30
Planas et al., Pathogens and Immunity, doi:10.20411/pai.v10i1.752 Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
In Vitro study showing significant escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP.3.3 with monoclonal antibodies pemivibart (VYD222) and sipavibart (AZD3152). Sipavibart lost antiviral efficacy, while pemivibart maintained reduced act..
Aug 14
Loubet et al., Human Vaccines & Immunotherapeutics, doi:10.1080/21645515.2024.2387221 Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
Retrospective 47 immunocompromised patients in France showing no adverse events with sipavibart, an investigational long-acting monoclonal antibody, as COVID-19 pre-exposure prophylaxis. The patients had various immunosuppressive conditio..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit